Med BioGene announces futher promising results on the diagnostic value of its lymphoma genetic biomarkers

05-Feb-2007

Med BioGene Inc. announced the results of its latest pre-clinical studies involving its gene expression Profiling System(TM) for diagnosing lymphoma. 110 RNA samples derived from human lymphoma tissues, representing the seven major subtypes of lymphoma, were analyzed utilizing a 10-fold cross-validation approach.

Using MBI's genetic biomarkers of between 50 and 100 genes per subtype, the Gene Expression Profiling System(TM) achieved an average accurate prediction rate of 88% in diagnosing the various lymphoma subtypes against other lymphoma subtypes. According to the accuracy data compiled, the median specificities for diagnosing the various subtypes averaged 97%, whereas the median sensitivities averaged 86%.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances